Literature DB >> 22462631

Bazedoxifene: a guide to its use in postmenopausal osteoporosis.

Gillian M Keating1, Katherine A Lyseng-Williamson, Sean T Duggan, Kate McKeage.   

Abstract

Oral bazedoxifene (Conbriza®) reduces the incidence of new vertebral fractures in patients with postmenopausal osteoporosis. It also appears to reduce the risk of nonvertebral fractures in high-risk patients. Bazedoxifene is generally well tolerated and does not appear to have detrimental effects on endometrial or breast tissue.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22462631     DOI： 10.2165/11207810-000000000-00000

Source DB:  PubMed          Journal:  Drugs Aging        ISSN： 1170-229X            Impact factor:   3.923


  14 in total

1.  Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial.

Authors:  T J de Villiers; A A Chines; S Palacios; P Lips; A Z Sawicki; A B Levine; C Codreanu; N Kelepouris; J P Brown
Journal:  Osteoporos Int       Date:  2010-06-10       Impact factor: 4.507

2.  Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity.

Authors:  Barry S Komm; Yogendra P Kharode; Peter V N Bodine; Heather A Harris; Chris P Miller; C Richard Lyttle
Journal:  Endocrinology       Date:  2005-06-16       Impact factor: 4.736

Review 3.  Bazedoxifene: a review of its use in the treatment of postmenopausal osteoporosis.

Authors:  Sean T Duggan; Kate McKeage
Journal:  Drugs       Date:  2011-11-12       Impact factor: 9.546

Review 4.  The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management.

Authors:  Dieter Felsenberg; Steven Boonen
Journal:  Clin Ther       Date:  2005-01       Impact factor: 3.393

Review 5.  Antifracture efficacy of currently available therapies for postmenopausal osteoporosis.

Authors:  Jean-Yves Reginster
Journal:  Drugs       Date:  2011-01-01       Impact factor: 9.546

6.  Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club.

Authors:  J-J Body; P Bergmann; S Boonen; Y Boutsen; J-P Devogelaer; S Goemaere; J-M Kaufman; S Rozenberg; J-Y Reginster
Journal:  Osteoporos Int       Date:  2010-05-18       Impact factor: 4.507

7.  Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women.

Authors:  David F Archer; JoAnn V Pinkerton; Wulf H Utian; José C Menegoci; Tobie J de Villiers; Chui Kin Yuen; Amy B Levine; Arkadi A Chines; Ginger D Constantine
Journal:  Menopause       Date:  2009 Nov-Dec       Impact factor: 2.953

Review 8.  Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development.

Authors:  Luigi Gennari; Daniela Merlotti; Fabrizio Valleggi; Giuseppe Martini; Ranuccio Nuti
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

9.  Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis.

Authors:  Catherine MacLean; Sydne Newberry; Margaret Maglione; Maureen McMahon; Veena Ranganath; Marika Suttorp; Walter Mojica; Martha Timmer; Alicia Alexander; Melissa McNamara; Sheetal B Desai; Annie Zhou; Susan Chen; Jason Carter; Carlo Tringale; Di Valentine; Breanne Johnsen; Jennifer Grossman
Journal:  Ann Intern Med       Date:  2007-12-17       Impact factor: 25.391

10.  Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled Phase 3 study of postmenopausal women with osteoporosis.

Authors:  Claus Christiansen; Charles H Chesnut; Jonathan D Adachi; Jacques P Brown; César E Fernandes; Annie Wc Kung; Santiago Palacios; Amy B Levine; Arkadi A Chines; Ginger D Constantine
Journal:  BMC Musculoskelet Disord       Date:  2010-06-22       Impact factor: 2.362
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.